UCB

TLDR

UCB is a Brussels-based global biopharmaceutical company listed on Euronext Brussels, focused on neurology and immunology medicines.

Overview

UCB (Union Chimique Belge) was founded on 18 January 1928 by Emmanuel Janssen in Brussels. The company started in industrial chemistry and gradually moved into pharmaceuticals through Meurice Laboratories, with an early research center established in the 1950s producing medicines such as Atarax. Over the following decades UCB transitioned from a diversified chemicals group into a focused biopharmaceutical company.

Today UCB is one of the largest Belgian companies on Euronext Brussels and a member of the Bel20 index. Its commercial portfolio centers on neurology (Vimpat, Briviact, Keppra) and immunology (Cimzia, Bimzelx), with a research footprint that spans Belgium, the United Kingdom, the United States and Japan. Headquarters are in the Anderlecht district of Brussels.

Jean-Christophe Tellier joined UCB in 2011 and became CEO on 1 January 2015. The Board has proposed renewing his mandate as CEO and director through 2030.

Key People

• Emmanuel Janssen - Founder
• Jean-Christophe Tellier - CEO

Listing

• Euronext Brussels: UCB (Bel20)

Connections

UCB is part of the Belgian biopharma cluster alongside argenx and Galapagos, with deep ties to academic research in Brussels and Flanders.

Links

• Website: https://www.ucb.com
• LinkedIn: https://linkedin.com/company/ucb